GlaxoSmithKline: Making an impact on emerging markets

Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of  emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Inspiring Leaders Podcast: Le...

Rob Hornby, Co-CEO of AlixPartners and Rita Clifton CBE, Portfolio Chair and Non-Executive Director (including Deputy Chair of the John Lewis Partnership, Chair of Simplyhealth, Chair of the international sustainability...

Inspiring Leaders Podcast: De...

Lucinda Charles-Jones, Non-executive Director & Chair or RemCo for Virgin Money and Rank Group (plus a Criticaleye Board Mentor) and Jim Devine, Group HRD, Spirax Group speak to us about some of the findings of our ...

Click here to download this insight
The Boards' Cyber-Risk Compas...

In this insight, Criticaleye Retreat Partner Palo Alto Networks shares the 10 questions every director should ask to govern, fortify and strategise their organisation’s approach to cyber risk.


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 408




Workday Concentrix London Stock Exchange Group Eightfold AI NatWest Group AlixPartners Rolls-Royce NATS Google Accenture Lightsource bp FTSE Women Leaders Review Salesforce Legal & General Aldermore Group E.ON UK Hitachi Solutions Worldpay Drax Group plc IBM Consulting GlaxoSmithKline plc British Land Palo Alto Networks